16 September 2026 editorial review · Item
OPT101 (CD40-pathway peptide): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27T00:00:00.000Z. - Claim check: Posted OPT101 Phase 1b results show no C-peptide advantage over placebo and 18 of 24 completing. Phase 2 recruitment is a future efficacy test. Conference immunophenotyping is not proof of clinical preservation.
- Registry NCT06964087: RECRUITING; updated 2026-04-06; enrollment 72 (ESTIMATED); primary completion 2026-05-31 (ESTIMATED); results not posted in retrieved record.
- Registry NCT05428943: COMPLETED; updated 2026-08-10; enrollment 24 (ACTUAL); primary completion 2024-02-21 (ACTUAL); results posted.
- Programme/sponsor/conference source boundary: Restoring Immune Homeostasis with a Novel Peptide — Phase 1b immunophenotyping (conference).